Key clinical point: Investigators identified a specific five-fraction radiotherapy schedule that was well tolerated and linked to fairly low rates of treatment-related toxicity.

Major finding: 12-Gy/fraction delivered in five fractions over the course of 1.5-2 weeks was associated with a 7.2% probability of dose-limiting toxicities within the first year.

Study details: NRG Oncology/RTOG 0813, a phase 1/2 study including 120 patients with centrally located non–small cell lung cancer enrolled at one of 43 U.S. and Canadian centers.

Disclosures: Authors reported disclosures related to AstraZeneca, Abbvie, Varian Medical Systems, Elekta, Accuray, Seattle Genetics, Celgene, Exelixis, Gilead Sciences, Illumina, Ions Pharmaceuticals, and EMD Serono, among others.